LifeMD Appoints New CMO, Elects Directors

Ticker: LFMDP · Form: 8-K · Filed: Jun 18, 2024 · CIK: 948320

Lifemd, INC. 8-K Filing Summary
FieldDetail
CompanyLifemd, INC. (LFMDP)
Form Type8-K
Filed DateJun 18, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $0.0001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-election, personnel

Related Tickers: LFMD

TL;DR

LifeMD brings in a new CMO and adds two independent directors to the board.

AI Summary

LifeMD, Inc. announced on June 14, 2024, that it has appointed Dr. Michael A. Grodin as its new Chief Medical Officer. Dr. Grodin, who previously served as Chief Medical Officer at Sollis Health, will lead LifeMD's clinical strategy and operations. The company also announced the election of two new independent directors, Ms. Jennifer L. Jones and Mr. David R. Miller, to its Board of Directors.

Why It Matters

The appointment of a new Chief Medical Officer and the addition of independent directors can signal a strategic shift or a strengthening of governance for LifeMD, potentially impacting its future direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key executive positions and board composition can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer of LifeMD?

Dr. Michael A. Grodin has been appointed as the new Chief Medical Officer of LifeMD.

When was the report filed?

The report was filed on June 18, 2024.

What is LifeMD's business address?

LifeMD's business address is 236 Fifth Avenue, Suite 400, New York, NY 10001.

Who are the newly elected independent directors?

Ms. Jennifer L. Jones and Mr. David R. Miller have been elected as new independent directors.

What was LifeMD's former company name?

LifeMD was formerly known as Conversion Labs, Inc. (name change 20180622), Immudyne, Inc. (name change 20120514), and IMMUDYNE INC (name change 19950720).

Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-06-18 16:10:16

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIFEMD, INC. Dated: June 18, 2024 By: /s/ Eric Yecies Eric Yecies General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing